Australia markets close in 26 minutes
  • ALL ORDS

    7,039.40
    +98.80 (+1.42%)
     
  • ASX 200

    6,785.80
    +112.50 (+1.69%)
     
  • AUD/USD

    0.7747
    +0.0035 (+0.46%)
     
  • OIL

    62.42
    +0.92 (+1.50%)
     
  • GOLD

    1,746.70
    +17.90 (+1.04%)
     
  • BTC-AUD

    59,705.08
    +545.14 (+0.92%)
     
  • CMC Crypto 200

    923.82
    -9.31 (-1.00%)
     
  • AUD/EUR

    0.6412
    +0.0029 (+0.45%)
     
  • AUD/NZD

    1.0654
    +0.0003 (+0.03%)
     
  • NZX 50

    12,301.81
    +74.52 (+0.61%)
     
  • NASDAQ

    12,909.44
    +81.14 (+0.63%)
     
  • FTSE

    6,483.43
    -168.53 (-2.53%)
     
  • Dow Jones

    30,932.37
    -469.63 (-1.50%)
     
  • DAX

    13,786.29
    -93.01 (-0.67%)
     
  • Hang Seng

    29,328.38
    +348.17 (+1.20%)
     
  • NIKKEI 225

    29,604.49
    +638.48 (+2.20%)
     

DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against GoodRx Holdings, Inc. – GDRX

Zhang Investor Law P.C.
·2-min read

NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=goodrx-holdings-inc&id=2531 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

如果您想加入这个集体诉讼案,请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=goodrx-holdings-inc&id=2531

If you wish to serve as lead plaintiff, you must move the Court before the February 16, 2021 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. According to the GoodRx class action lawsuit, given defendants’ knowledge of Amazon’s intention to enter the online pharmaceutical business, their statements in the Registration Statement and during the Class Period about GoodRx’s competitive position were materially false and/or misleading when made and caused GoodRx Class A common stock to trade at artificially inflated prices of more than $64 per share during the Class Period.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
info@zhanginvestorlaw.com
tel: (800) 991-3756